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Hepatitis CMany viral genomes encode small, integral membrane proteins that form homo-oligomeric channels in mem-
brane, and they transport protons, cations, and other molecules across the membrane barrier to aid various
steps of viral entry and maturation. These viral proteins, collectively named viroporins, are crucial for viral path-
ogenicity. In the past ﬁve years, structures obtained by nuclear magnetic resonance (NMR), X-ray crystallogra-
phy, and electron microscopy (EM) showed that viroporins often adopt minimalist architectures to achieve
their functions. A number of small molecules have been identiﬁed to interfere with their channel activities and
thereby inhibit viral infection, making viroporins potential drug targets for therapeutic intervention. The
known architectures and inhibitionmechanisms of viroporins differ signiﬁcantly from each other, but some com-
mon principles are shared between them. This review article summarizes the recent developments in the struc-
tural investigation of viroporins and their inhibition by antiviral compounds. This article is part of a Special Issue
entitled: Viral Membrane Proteins—Channels for Cellular Networking.
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The past few decades of virus research have witnessed the emer-
gence and growth of a special family of membrane-embedded channel
proteins encoded by the genome of viruses [1–3]. This family ofmbrane Proteins—Channels for
ou).
ights reserved.proteins, collectively termed viroporins, generally has very low se-
quence homology with the ion channels from prokaryotes and eukary-
otes, though certain transmembrane (TM) segments can be similar [4].
Viroporin proteins share some common features; they are small (50–
120 amino acids), hydrophobic, and often dynamic, and due to the
small size, these membrane proteins must oligomerize in order to
formchannels.Moreover, these viral channels appear to adoptminimal-
ist but functional structural solutions that are drastically different
from the known channel structures from other organisms, making
structural and functional exploration of viroporins both interesting
and rewarding.
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cluding 2B of poliovirus, 6K of togavirus, and M2 from inﬂuenza A virus
(IAV). The 2B is a well-known viroporin implicated in membrane per-
meabilization to ions and small molecules during later stages of viral in-
fection [5–7]. The 6K has been shown to form cation-selective channels
when inserted into lipid bilayers [8], but the role of 6K in the viral life
cycle is still poorly characterized [9–11]. The M2 proton channel has
by far received the biggest spotlight because 1) it is the target of the
once successful anti-ﬂu drug (amantadine or rimantadine) and 2) it is
a pH-dependent proton conducting channel (our knowledge of proton
channel has for a long timebeen very limited) [12–14]. Since the discov-
ery of above proteins, the viroporin family has grown substantially
(Table 1). The human immunodeﬁciency virus type 1 (HIV-1) Vpu and
the hepatitis C virus (HCV) p7 have been shown to conduct cations
[15–19]. The inﬂuenza B viral genome encodes the BM2 protein that is
a functional homolog of M2 but is not sensitive to the adamantane fam-
ily of drugs [20]. There is the viral K+ channel from Parameciumbursaria
chlorella virus 1 (PBCV-1) that contains the selectivity ﬁlter of the pro-
karyotic and eukaryotic K+ channels [21] and was proposed to adopt
similar structure as KcsA [22]. Apart from the ion channels, poliovirus
developed a VP4 channel that permeates single-stranded RNA across
the membrane [23], further expanding the list of substrates that
viroporins transport.
The exact functions of viroporins inmany viruses are not yet known,
though their roles have been implicated in entry, viral assembly and
viral release. In particular, the roles of theM2 proton channel during in-
ﬂuenza replication havemore or less been accepted. One role of theM2
channel is to equilibrate pH across the viralmembrane during cell entry,
which acidiﬁes the virion interior after endocytosis and facilitates
RNA release [24,25]. Another role of M2 is to equilibrate pH across
the trans-Golgi membrane of infected cells during viral maturation,
which preserves the pre-fusion form of hemagglutinin through de-
acidiﬁcation of the Golgi lumen [26]. The roles of other cation-
selective viroporins are however not so clear. In the case of HCV, the
p7-mediated channel activity has been reported to facilitate virus re-
lease [27,28]. In fact, one of the general roles proposed for viroporin is
to depolarize either the endoplasmic reticulum (ER) or plasma mem-
brane to facilitate membrane curvature during budding [3,29]. Another
general role for viroporin is to simply cause cation leakage and cellular
stress, which would induce programmed cell death [30]. In addition to
ion permeation, several viroporins are known to participate in viral as-
sembly through interaction with other proteins. For example, the IAV
M2 and IBV BM2 proteins both have signiﬁcant cytoplasmic domains
that are involved in recruiting matrix proteins M1 during virus assem-
bly [31–33]. The HCV p7 protein has also been reported to interactTable 1
List of identiﬁed viroporin proteins.a









IAV M2 97 Tetramer H+ Ref. [37,38,74]
IBV BM2 115 Tetramer H+ Ref. [39]
HCV p7 63 Hexamer Cation Ref. [18,62]
HIV-1 Vpu 81 Pentamer Cation Ref. [70,71,90]
SARS-CoV 3a 274 Tetramer K+ Ref. [72]
E 76 Pentamer Na+, K+ Ref. [91]
Alphavirus 6 K 61 N/A b Na+, K+, Ca2+ Ref. [8]
Poliovirus VP4 68 N/A b RNA Ref. [23]
2B 97 N/A b Ca2+ Ref. [7,92]
HPV E5 83 N/A b N/A Ref. [93,94]
PBCV-1 Kcv 94 Tetramer K+ Ref. [21,95]
a The viruses listed are inﬂuenza A virus (IAV), inﬂuenza B virus (IBV), hepatitis C
virus (HCV), human immunodeﬁciency virus type 1 (HIV-1), severe acute respiratory
syndromes-associated coronavirus (SARS-CoV), alphavirus, poliovirus, human papilloma-
virus (HPV), and Paramecium bursaria chlorella virus 1 (PBCV-1).
b Pore formation indicated but a deﬁned oligomeric state either does not exist or is not
characterized.with other non-structural proteins such as NS2, and this interaction ap-
pears to be crucial for the production of infectious HCV particles [34,35].
While the precise functions of ion conduction activity of many
viroporins remain to be discovered, advances in structural characteriza-
tion of inﬂuenza M2, BM2 and HCV p7 proteins have provided compel-
ling evidences that viroporins are not simple porins but can adopt
interesting architectures for regulated transport activities such as pH
dependent proton transport and selective cation conductance. Further-
more, structural characterizations of interactions between viroporins
and small molecule inhibitors have revealed conceptually very different
mechanisms bywhich these channel proteins can be inhibited, and thus
alluded to newopportunities of using viroporins as antiviral targets. The
current review describes the recently characterized viroporin architec-
tures, their intriguing and minimalist modes of assembly, and how the
new structural information explains the observed functional properties
of the viroporins. This review also describes examples of viroporins
being inhibited by the known antiviral drugs and explains the mecha-
nism of drug inhibition and drug resistance.
2. The architectures of viroporins
Structural studies of viroporins have not been easy because these
small membrane proteins are typically dynamic and very sensitive to
the hydrophobic surroundings. In the last ﬁve years, multiple biophysi-
cal techniques including solution NMR, X-ray crystallography, solid-
state NMR, and EM have been used to gradually ﬁll the knowledge
gap. For example, there are now structural information of the channel
domain ofM2 in crystal and solution states, in lipid bilayer, under differ-
ent pHs, and bound to different small molecules. These complementary
structural data allow elucidation of the functional mechanism from dif-
ferent view angles. In addition to the inﬂuenza proton channels, the
structure of the full-length p7 channel of HCV has recently been deter-
mined. In both cases, structure determination revealed unexpected
structural features that are important for understanding the functional
mechanism.
2.1. The inﬂuenza M2 channels: structural solutions for proton conduction
The M2 protein of IAV and BM2 protein of IBV are 97- and 109-
residue single-pass membrane proteins, respectively, that form
homotetramers in membrane [36–40]. The two proteins share almost
no sequence homology except for the HxxxW sequence motif in the
TM domain that is essential for channel activity. Their domain arrange-
ments are also different. The TM region encompasses residues 24–46 in
M2 and residues 4–33 in BM2. Hence the unstructured N-terminal seg-
ment preceding the TM domain is much longer in M2 and has been
sought after as a possible target for vaccine development [41–45]. In ad-
dition to the membrane-embedded channel domain, M2 and BM2 both
have relatively large C-terminal cytoplasmic regions. These regions
have been suggested to play a role during viral assembly, by recruiting
the matrix proteins to the cell surface during virus budding and/or by
contributing to the coating of matrix proteins to the viral envelope
[31,32,46,47].
The ﬁrst detailed structures of the M2 channel were determined
concurrently by solution NMR spectroscopy and X-ray crystallography
in 2008 [48,49]. Subsequent X-ray and solution NMR studies deter-
mined the structures of the channel domain under different condi-
tions [50] and with different drug resistance mutations [51,52].
Moreover, structural characterization by solid-state NMR spectroscopy
also generated working structural models for the M2 channel in the
lipid bilayer environment [53,54]. The above structures solved under
different conditions show substantially different conformations
(Fig. 1A), suggesting that the assembly of the M2 channel is quite dy-
namic and is sensitive to the reconstitution environment. This structural
plasticity could have been one of themajor factors that caused technical
difﬁculties for structure determination.
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converged to a common mode of channel assembly: a left-handed
four-helix bundle forms the channel pore, and tetramerization of the
four TM helices is further stabilized by intermolecular contacts between
C-terminal amphipathic helices ﬂanking the TM domain [48,54]. This
mode of TM helix assembly places the “H” and “W” of the HxxxW se-
quence motif inside the channel. Four imidazole rings of His37, which
are pH trigger devices and are essential in transporting protons, are
packed closely inside the pore. Moreover, packing of the Trp41 indoles
creates a channel gate, which occludes the C-terminal end of the pore.
The detailed structure of the BM2 channel domain was solved
using solution NMR methods [33]. The BM2 channel is also assembledFig. 1. Structures of the inﬂuenza proton channels and mechanism of proton conduction. (A) Th
the solution NMR structures of the wildtype and the V27A mutant determined using residue
determined at pH 7.3 and pH 6.5, respectively. The structures 2L0J and 2KQT were obtained us
22-46, respectively. (B) Solution NMR structures of the BM2 protein. The PDB codes 2KIX and 2K
(residues 43–103), respectively. (C) Isolated view of the pore-lining histidine and tryptophan
(3LBW) and NMR structure (2RLF) of M2 and NMR structure of BM2 (2KIX). (D) Cartoon of the
siently enlarge the N-terminal opening, allowing protons to be relayed cross the Val27 barrier.
Trp41 gate. (3) C-terminal water molecules accept protons from protonated His37. (4) Polar rethrough left-handed helical packing but unlike M2, the packing shows
strong coiled-coil characteristics with regular heptad repeats [12]
(Fig. 1B). In the BM2 coiled-coil tetramer, positions a and d of the heptad
repeats are occupiedmostly by serines andHis19 to form thehydrophil-
ic pore. Positions g and e are occupied by leucines and phenylalanines,
respectively, to allow for hydrophobic packing between the peripheral
leucines and phenylalanines. This arrangement for coiled-coil assembly
in membrane is the opposite to that of water-soluble coiled-coil tetra-
mer, in which positions a and d are typically hydrophobic residues
and positions g and e are polar residues [55]. The inverse coiled-coil as-
sembly in membrane places the histidine (His19) and tryptophan
(Trp23) of the HxxxW motif inside the pore. The cytoplasmic domaine many structures of the inﬂuenza M2 channel. The PDB codes 2RLF and 2KWX represent
s 18–60. The 3C9J and 3LBW are crystal structures of the TM domain (residues 22–46)
ing solid-state NMR using protein constructs that encompass residues 22–62 and residues
J1 represent the structures of the TMdomain (residues 1–33) and the cytoplasmic domain
sidechains in M2 and BM2 channels. Images are from the high resolution crystal structure
mechanism of proton conduction. (1) Channel breathing due to thermal energy can tran-
(2) The protons bind to His37 imidazole, and protonation of His37 triggers opening of the
sidues Asp44 and Arg45 facilitate proton exit.
Fig. 1 (continued).
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and has strong bipolar distribution of surface charged residues. This do-
main speciﬁcally interacts with the M1 matrix protein [33].
The structural arrangement of the histidine and tryptophan inside
the pore in M2 and BM2 implies the roles of imidazoles as proton selec-
tion devices and indoles as channel gates (Fig. 1C). Indeed, functional
assays [56] andNMRmeasurements [57] suggested that proton conduc-
tion across the M2 channel involves cycles of histidine protonation and
deprotonation, and that the histidines serve as proton shuttling devices.
A concern of histidine protonation is that when multiple histidines are
protonated, the charge repulsion between them would be strong
enough to destabilize the tetramer. This issue can however be resolved
by the fact that not all histidines can be protonated at the same time be-
cause protonation of one histidine would increase the barrier for the
protonation of another histidine [58]. Indeed, multiple pKa values
have been observed in proton conduction assays of M2 [56]. Therefore,
our current understanding of the proton conduction mechanism is that
the His-Trp structural elements constitute the minimally required unit
for pH-dependent proton transport (Fig. 1D). It was proposed in Ref.
[58] that in the closed state two pairs of histidines in the tetramer
each share one proton, which explains the high pKa ~8.2. Lowering pH
results in the protonation of the third histidine from the N-terminal
side that, in turn, results in disruption of the two histidine dimers
and proton conduction. The remaining question to be addressed in the
future is how does the third protonation result in conformational
change of the tryptophan that would allow relaying the proton to the
C-terminal side of the tryptophan gate [56]. Finally, the signiﬁcantstructural differences between the M2 and BM2 channels show
strong ability of inﬂuenza virus to evolve different solutions to
achieve the same goal.
2.2. The funnel architecture of the p7 channel
The viroporin protein p7 encoded by the HCV genome is a 63-residue
protein that oligomerizes in membrane to form cation-selective chan-
nels [18,19], with higher selectivity for Ca2+ than K+/Na+ [59,60]. The
channel activity of p7 is important for the assembly and release of infec-
tious viruses, although the molecular mechanism of this function re-
mains elusive [27,28]. As in the case of M2, structural characterization
of p7was confrontedwith challenges of preparing concentrated and ho-
mogeneous sample of p7 oligomers. Earlier NMR studies found that the
p7 monomer has three helical segments: two in the N-terminal half of
the sequence and one near the C-terminus [60,61]. These NMR studies
were performed under conditions that are believed to support the mo-
nomeric state of p7. Although themonomeric state is unlikely to conduct
ions, it could be involved in interactingwith theNS2 protein during virus
assembly [34,35]. The ﬁrst structural investigation of the assembled p7
oligomer was conducted using single-particle EM, which obtained a
16 Å resolution electron density map of the protein complex [62]. The
map shows that the p7 from HCV genotype 2a (JFH-1 strain) forms a
42 kDa hexamer and adopts a ﬂower-like shape that does not resemble
any of the known ion channel structures in the database. While the
above structural investigations validated p7 as a stable hexameric com-
plex, the structural details required for understanding ion conduction
1062 B. OuYang, J.J. Chou / Biochimica et Biophysica Acta 1838 (2014) 1058–1067and drug inhibition remained unknown. Recently, an effective solution
NMR system of the p7 hexamer was established using p7 from genotype
5a (EUH1480 strain), which is one of the less hydrophobic sequences
among the p7 variants. Using the NMR system, the detailed structure
of the p7 hexamer was eventually determined [63].
The NMR structure of the p7 channel shows that HCV has developed
a solution to conduct cations that is substantially different from any of
the known K+ or Ca2+ channels. The channel has a funnel-like architec-
ture with six minimalist chains, each containing three helical segments,
H1, H2 and H3. The H1 and H2 helices of the monomers form the nar-
row and wide regions of the funnel-shaped cavity, respectively, and
the H3 helices wrap the channel peripheral by interacting with H2 of
the i + 2 and H1 of the i + 3 monomers (Fig. 2A). There are no
intramonomer contacts between the three helical segments in the con-
text of the hexamer. The high order of oligomerization and the maxi-
mized interactions between the monomers allow a small hydrophobic
peptide (63-residues) to form a 42 kDa channel complex.
Although having a minimalist architecture compared to other Ca2+
orMg2+ channels, the p7 hexamer appears to possess essential features
of ion channels: 1) pore elements that support selective ion dehydra-
tion; 2) a gate or constriction that prevents non-speciﬁc permeation,
but can open in response to regulating factor such as pH, voltage, ligand,
or the ion of selection itself [64–66]. The channel interior of p7 has a
number of strongly conserved residues that are likely candidates to
serve the above functions. The most obvious one is Asn9, which forms
a ring of carboxamide near the narrow end of the channel (Fig. 2B).
Residue 9 is asparagine in all strains except being substituted with his-
tidine in genotype 2 viruses. Formation of a ring of carboxylates or
carboxamides has been a recurring theme in prokaryotic and eukaryotic
channels that have selectivity for divalent cations. For examples, central
to the CorA Mg2+ channel is the pentameric ring of asparagines [67].
Moreover, the recent structure of the calcium release-activated calciumFig. 2. The funnel architecture and pore elements of the p7 channel. (A) NMR structure of the p7
of the channel. Right panel: global arrangement of H1, H2 and H3 helical segments in the ass
hexamer. (B) Pore-lining elements of the p7 channel. Left panel: cutaway view of the channel s
bers next to the helical segments represent the monomers to which the helices belong. Right
formed with Asn9 sidechains.(CRAC) channel Orai shows a hexameric ring of aspartic acids [68].
These channels all have strong selectivity for divalent cations, although
they can also conduct monovalent cations such as Na+ and K+.
Proximal to the Asn9 ring of p7 is the hydrophobic ring formed by
Ile6, which deﬁnes the narrowest point of the channel. Residue 6 is iso-
leucine or valine throughout HCV genotypes and subtypes. Therefore, a
narrow hydrophobic ring at this position likely serves as a hydrophobic
constrictionwhichpreventswater from freely passing through. Amech-
anism of cation conduction can be envisaged from the structure. The
role of the Asn9 ring is to provide ion selectivity by recruiting and
dehydrating cations near the funnel exit, and the unhydrated cations
can pass the hydrophobic ring. In this regard, the Asn9 has the feature
of being a broad selectivity ﬁlter.
In addition to what appears to be the cation selectivity ring near the
narrow, N-terminal exit of the channel, the wider, C-terminal entrance
of the channel is decoratedwith a conserved ring of arginines or lysines.
Placement of a positively charged ring at the entrance was incompre-
hensible to us initially because it may repel cations. But an earlier
study reported that a designed TM barrel with internal arginine–histi-
dine dyads forms efﬁcient cation selective channels [69] because the im-
mobile arginines can recruit mobile anions, which in turn facilitate
cations to diffuse through the pore. It is interesting to note that a highly
basic region containing Arg155, Lys159 and Lys163 in the pore was also
found in the CRAC Orai structure [68]. One possible role of these basic
residues in cation selective channels is binding and obstructing anions
while allowing cations to diffuse into the pore. This mechanism would
be consistentwith the observation that replacing Arg35with negatively
charged aspartic acid largely abrogated conductance [63].
Finally, an unresolved issue with the NMR structure is that the size
of the Asn9 ring (inner diameter ~ 7 Å) is signiﬁcantly larger than
those in, e.g., the CRAC and CorA crystal structures. At this size, the
carboxamide ring clearly cannot provide tight coordination of Ca2+,hexamer. Left panel: cartoon (cylinder) representation illustrating the funnel architecture
embled hexamer, showing that the i and i + 3 monomers form a symmetric pair in the
howing the pore-lining residues, with residues in red being strongly conserved. The num-
panel: the view of the N-terminal opening of the channel showing the carboxamide ring
1063B. OuYang, J.J. Chou / Biochimica et Biophysica Acta 1838 (2014) 1058–1067and this raises a number of questions that need to be addressed in the
future. Does the NMR structure, solved in the absence of Ca2+ and in-
hibitors, represent the open or closed state of the channel (if the two
states exist)? Is Ca2+ selectivity of p7 as strong as the highly regulated
Ca2+ channel such as CRAC? Or was p7 developed as a general,
unspeciﬁc cation channel for the purpose of dissipating membrane po-
tential? Addressing these questions would require further structural
investigation of p7 under different conditions andmore extensive char-
acterization of the channel conductance properties by single-channel
measurements. From structural perspective, the funnel-like architec-
ture is formed with multiple helical segments connected by hinges
and short loops and we believe that this ﬂexibility can afford the dy-
namic opening and closing of the tip of the channel.
2.3. Other viroporins
In addition to the above viroporin structures, structural characteriza-
tion has been conducted for several other viroporins. Combined use of
solid-state NMR PISEMA experiment and solution NMR ﬁrst identiﬁed
themembrane-associated region of the Vpu protein fromHIV-1 includ-
ing a TM helix and a juxtamembrane amphipathic helix parallel to
the membrane [16]. The same research group obtained a more
detailed structure of the TM helix and its tilt angle relative to the lipid
bilayer, and in combination with computational modeling, provided a
homopentameric model of the Vpu channel [70]. A somewhat different
model of the pentameric Vpu was recently developed using inter-
monomer distance restraints from magic angle spinning (MAS) NMR
experiments, suggesting that Vpu, like M2 and p7, also adopts substan-
tial structural variability [71]. In addition to Vpu, the oligomeric state
analyses have been performed for the Kcv protein from PBCV-1 [22],
and the 3a and E proteins from SARS-CoV [72,73]. These studies sug-
gested that Kcv and 3a form homotetramers while the E protein forms
a stable pentamer.We believe that these viroporinsmay adopt interest-
ing architectures as well to transport ions.
3. Drug inhibition of viroporins
One of themotivations for investigating viroporins is their anticipat-
ed structural difference with human channels and thus the potential
as antiviral drug targets. A successful example of antiviral drug that tar-
gets viroporin is amantadine (Symadine) or rimantadine (Flumadine),
which inhibits proton conduction of the M2 channel [74,75] and was
the ﬁrst licensed drug for treating inﬂuenza infections [76]. Rimantadine
has also been shown to inhibit theHCVp7 channel [18,77]. Since theﬁrst
successful drug targeting a viroporin, researches on viralmembrane pro-
teins have identiﬁed several more viroporin inhibitors with varying efﬁ-
cacies, including hexamethylene amiloride that inhibits HIV-1 Vpu [17],
HCV p7 [59,60] and E from SARS-CoV [78], long-alkyl-chain iminosugar
derivatives that inhibit HCV p7 [19], as well as a new compound,
BIT225, that inhibits HIV-1 Vpu [79] and HCV p7 [80].
3.1. Amantadine inhibition of M2 channel
Themechanismof how amantadine/rimantadine inhibitM2 channel
has been elusive until very recently. Previous confusion came mainly
from the multiple binding sites that have been observed experimental-
ly. In a crystallographic study of the M2 TMdomain (residues 24–46) in
the presence of amantadine, the drug density was found inside the
channel near residue Ser31, but at structural resolution of 3.5 Å, it was
difﬁcult to conﬁrm the position of amantadine binding [49]. At the
same time, however, a solution NMR study of a longer version of M2
(residues 18–60) showed that rimantadine binds to an external, lipid-
facing pocket around residue Asp44 between adjacent TM helices [48].
The mechanistic implications of the two binding sites are obviously dif-
ferent. One is the drug directly blocking the channel passage, and the
other is an allosteric mechanism by which drug binding to the externalsite favors the closed state of the channel. Subsequent solid-state
NMR measurements of the TM domain in lipid bilayer showed that
rimantadine binds to both sites, with higher afﬁnity for the pore site
[53]. Functional studies using an AM2–BM2 chimera protein provided
the strongest evidence that the pore binding site is the primary site of
drug inhibition [81,82]. In this study, the authors used a chimera of
M2 variants from inﬂuenza A and B viruses that contains only the
pore-binding site which showed that the chimera channel is still sensi-
tive to amantadine or rimantadine inhibition, indicating that the pore-
binding site is the primary site of drug inhibition. Later, the structure
of the TM domain of the chimera in complex with rimantadine was de-
termined by NMR, providing a precise view of the drug binding inside
the channel pore [83].
The structure shows that eight methyl groups of the M2 tetramer
(two from each subunit: Val27 Cγ1H3 and Ala30 CβH3) together form a
deep internal pocket that completely wraps the adamantane cage of
the drug (Fig. 3A). The nitrogen of the rimantadine amino group is on
average 2.8 Å from the backbone carbonyl oxygen of Ala30 of one of
the four subunits, probably forming a hydrogen bond. The terminal
methyl group of the rimantadine is in the middle of the pore, facing
the open space in the channel around the Gly34 position. The structure
also shows that rimantadine binding is slightly tilted: its vertical axis is
on average ~20° from the C4 symmetry axis of the channel. The tilt
angle is consistent with the amantadine tilt in theM2 channel observed
with solid-state NMR spectroscopy [53].
Although amantadine or rimantadine has been widely used as anti-
inﬂuenza drug for decades, drug resistant variants are widespread, with
resistance now N90% [84]. The reported mutations that confer resis-
tance include V27A, A30T, S31N, and G34E, among which S31N and
V27A account for the vast majority of resistant strains [85,86]. It is obvi-
ous from the rimantadine-bound NMR structure that V27A and A30T
will change the size and/or hydrophobicity of the adamantane binding
pocket. The G34E mutation is likely to cause steric collision with the
amino and methyl groups of the drug. Moreover, introducing four neg-
ative charges inside the small pore could alter the channel conforma-
tion. The S31N mutation is less straightforward to explain because
Ser31 faces the helix–helix interface and does not appear to be involved
in any direct interactions with the drug. Previous NMR analysis of the
S31N mutant suggested that replacing Ser31 with the much bulkier
asparagine has the effect of destabilizing helical packing [51]. We be-
lieve that the S31N mutation abrogates drug binding allosterically by
disrupting or loosening the internal binding pocket. Modifying the
adamantane compound to overcome this mutation is clearly not easy,
but a recent study reported that conjugation of a \CH2-heteroaryl
group to the amine of amantadine leads to signiﬁcant inhibition of the
S31N mutant [87].
3.2. Inhibition of the p7 channel by the adamantane compounds
In addition to blocking the M2 channel, the adamantane derivatives
such as amantadine and rimantadine have also been reported to pose
some inhibitory effects on the p7 channel conductance [18,88]. The
therapeutic relevance of this ﬁndingwas however controversial in clin-
ical trials that investigated p7 amino acid variations in response to
antiviral therapy with amantadine [89]. When treating HCV genotype
1a/b infected patients with amantadine in the clinical study, no signiﬁ-
cant correlation of overall amino acid variations in p7 with response to
the treatment was found, although a p7 mutation, L20F, was observed
more often in the drug resistant patients. Another in vitro study using
single-channel recording technique showed that the activity of p7
from genotype 1b is not sensitive to amantadine [60]. The above dis-
crepancies around amantadine inhibition could be explained by the se-
quence variations of p7 among the different genotypes. Indeed, a
systematic investigation using multiple functional readouts including
viral entry and release demonstrated substantial genotype-dependent
and subtype-dependent sensitivity to several p7 inhibitors, including
Fig. 3. The amantadine and rimantadine binding sites in the M2 and p7 channels. (A) The precise NMR structure of rimantadine bound to the internal pocket of the AM2–BM2 chimeric
channel determined in DHPCmicelles and at pH 7.5 [83]. Left panel: detailed illustration of themethyl groups (in green) that interact with the adamantane cage. Right panel: surface rep-
resentation for showing the hydrophobic pocket that ﬁts the drug snuggly. One of the four subunits is omitted for drug visibility. (B) The amantadine or rimantadine binding site of the p7
channel determined byNMR inDPCmicelles and at pH 6.5 [63]. Left panel: the drug binds to six equivalent hydrophobic pockets of the p7 channel. Right panel: a close viewof amantadine
docked into the binding pocket as determined using NMR NOE restraints.
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not sufﬁciently localized to enable elucidation of the drug binding
location.
Themost recent structural characterization of HCVp7 provided a de-
tailed view of the binding site of amantadine or rimantadine [63]. NMR
measurements of the channel-drug complex revealed that amantadine
or rimantadine binds to six equivalent hydrophobic pockets (due to
the six-fold symmetry of the p7 channel) between the pore-forming
and peripheral helices (Fig. 3B). In each site, Leu52, Leu53, and Leu56
fromH3 of the i monomer, Val25 and Val26 fromH2 of the i + 2mono-
mer, and Phe20 from H2 of the i + 3 monomer together form a deep
hydrophobic pocket that wraps around the adamantane cage of the
drug. The amino group of amantadine or rimantadine is facing the large-
ly hydrophilic channel lumen. An important property of the drug bind-
ing site is that it consists of elements from different helical segments
and from differentmonomers. As rationalized above, permeation of cat-
ions through the p7 channel may depend on opening the narrow end of
the funnel, which in turn depends on the reorientation of the helical
segments. The binding of adamantane derivatives to the pocketmay in-
hibit channel activity allosterically by causing the channel to close.
3.3. The same drug, different viroporins, and different modes of inhibition
Comparing the amantadine or rimantadine bindingmode of HCV p7
to that of inﬂuenzaM2 shows two fundamentally differentmechanisms
of drug inhibition. In the case of M2, one drug binds to one channel.
Drug binding inhibits proton transport by directly blocking the channel
passage; it also prevents channel from opening. In the case of p7,amantadine and rimantadine are clearly too small to block the channel.
They instead bind to six equivalent sites outside of the channel cavity,
which can afford up to six drugs per channel. If rimantadine binding
to this site is relevant to inhibition, as crudely suggested by previous
functional mutagenesis, drug binding to these sites inhibits cation con-
duction with an allosteric mechanism, possibly by stabilizing the closed
state of the channel.
Although themechanisms of drug inhibitionmay be completely dif-
ferent, the structural bases that govern drug-binding afﬁnity for M2 and
p7 are actually similar, and they involve hydrophobicity and size of the
pocket, and position of the drug amino group. In the case of theM2 tet-
ramer, the drug adamantane cage ﬁts snuggly in a hydrophobic pocket
formed by eight methyl groups from Val27 and Ala30 (two from each
subunit), while the drug amino group forms polar contact with the
backbone oxygen of Ala30 and points to the polar region of the channel
cavity (Fig. 4A). For the p7 channel, the adamantane cage is in contact
with ten methyl groups and an aromatic group from the protein.
These hydrophobic groups form a deep hydrophobic pocket that also
matches closely the size of the adamantane cage (Fig. 4B). The amino
group of amantadine or rimantadine points to the channel lumen; it is
in position to form polar contacts with the electronegative groups
such as backbone carbonyl of residues 15–17.
The similarity in amantadine or rimantadine binding between p7
andM2 allude to similarmechanism of drug resistance. Known drug re-
sistance mutations of M2 such as V27A and A30T confer resistance by
decreasing the hydrophobicity of the adamantane binding pocket, and
this is conceptually consistent with the observed mutations that confer
drug resistance in p7. In the case of p7, our functional assay showed that
Fig. 4. Comparison between adamantane binding sites of inﬂuenzaM2 and HCV p7 channels. (A) The internal pocket that wraps around the adamantane cage of rimantadine determined
earlier for the AM2–BM2 chimeric channel [83]. The AM2–BM2 chimeric channel is awell-behavedmodel system for studying inﬂuenzaM2 channels; its N-terminal half is from inﬂuenza
A M2 protein (sensitive to amantadine or rimantadine inhibition) and its C-terminal half is from inﬂuenza B M2 protein (insensitive to amantadine or rimantadine). One subunit of the
tetrameric complex is removed to unveil the channel interior. (B) The peripheral pocket between the H2 and H3 helices to which amantadine binds [63]; it is a representative pocket
among six equivalent pockets in the p7 hexamer.
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also signiﬁcantly reduced rimantadine inhibition (unpublished data),
and these mutations all decrease hydrophobicity of the adamantane
binding pocket. Thus variations in thehydrophobicity of the adamantane
binding pocket among the p7 variants explain the large differences in
drug efﬁcacies observed between different HCV genotypes.
4. Conclusion
Viruses have developed membrane-embedded viroporins for trans-
port of ions and solutes during viral life cycle. The name “porin” seems
to imply leaky pores, similar to the β-barrel porins in bacteria. But, the
recent structural data show that these viroporins aremore sophisticated
than leaky pores. Although viroporins generally adoptminimalist archi-
tecture, they have the essential structural elements compatible with se-
lective transport of protons and/or cations. These viral channelsmaynot
be as functionally robust or speciﬁcally regulated as some of their coun-
terparts in prokaryotes and eukaryotes, because viruses often do not
need intricate regulation of channel activities during their infection
cycles. Nonetheless, the unique structures of viroporins can provide
unique opportunities for developing novel antiviral therapeutics.
We believe, with multiple biophysical and biochemical tools being
established for structural studies of membrane proteins, new viroporin
architectures will be discovered at a faster pace. Despite the progress in
structure determination, major challenges lie ahead in viroporin re-
search. The precise functional roles of many viroporins are still unclear.
Moreover, due to the lack of robust single-channel recording setups
suitable for viroporins, the ion conductance properties of most
viroporins have not been fully characterized. Therefore, better deﬁni-
tion of the functional aspects of viroporins will certainly draw greaterenthusiasm for developing therapeutics that target this interesting fam-
ily of membrane channels.
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